Measuring windows of selection for anti-malarial drug treatments.

Article English OPEN
Kay, Katherine (2015)
  • Publisher: BioMed Central
  • Journal: Malaria Journal, volume 14 (eissn: 1475-2875)
  • Related identifiers: doi: 10.1186/s12936-015-0810-4, pmc: PMC4521485
  • Subject: Infectious Diseases | qv_256 | Artemisinin combination therapy | Malaria | wc_765 | Modelling | Research | qv_38 | wc_750 | Window of selection | Pharmacodynamic | Drug resistance | Pharmacokinetic | Parasitology

Background The long half-lives of malaria ‘partner’ drugs are a potent force selecting for drug resistance. Clinical trials can quantify this effect by estimating a window of selection (WoS), defined as the amount of time post-treatment when drug levels are sufficiently high that resistant parasites can re-establish an infection while preventing drug-sensitive parasites from establishing viable infections. Methods The ability of clinical data to accurately estimate the true WoS was investigated using standard pharmacokinetic–pharmacodynamic models for three widely used malaria drugs: artemether–lumefantrine (AR-LF), artesunate–mefloquine (AS-MQ) and dihydroartemisinin–piperaquine (DHA-PPQ). Estimates of the clinical WoS either (1) ignored all new infections occurring after the 63-day follow-up period, as is currently done in clinical trials, or, (2) recognized that all individuals would eventually be re-infected and arbitrarily assigned them a new infection day. Results The results suggest current methods of estimating the clinical WoS underestimate the true WoS by as much as 9 days for AR-LF, 33 days for AS-MQ and 7 days for DHA-PPQ. The new method of estimating clinical WoS (i.e., retaining all individuals in the analysis) was significantly better at estimating the true WoS for AR-LF and AS-MQ. Conclusions Previous studies, based on clinically observed WoS, have probably underestimated the ‘true’ WoS and hence the role of drugs with long half-lives in driving resistance. This has important policy implications: high levels of drug use are inevitable in mass drug administration programmes and intermittent preventative treatment programmes and the analysis herein suggests these policies will be far more potent drivers of resistance than previously thought. Electronic supplementary material The online version of this article (doi:10.1186/s12936-015-0810-4) contains supplementary material, which is available to authorized users.
  • References (34)
    34 references, page 1 of 4

    1. WHO Guidelines for the treatment of malaria (second edition) (2010). World Health Organization, Geneva,

    2. Sisowath C, Strömberg J, Mårtensson A, Msellem M, Obondo C, Björkman A et al (2005) In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis 191:1014-1017

    3. Sisowath C, Ferreira PE, Bustamante LY, Dahlström S, Mårtensson A, Björkman A et al (2007) The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop Med Int Health 12:736-742

    4. Hastings IM, Watkins WM, White NJ (2002) The evolution of drug-resistant malaria: the role of drug elimination half-life. Phil Trans R Soc Lond B 357:505-519

    5. Hastings IM, Watkins WM (2006) Tolerance is the key to understanding antimalarial drug resistance. Trends Parasitol 22:71-77

    6. Watkins WM, Mosobo M (1993) Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg 87:75-78

    7. von Seidlein L, Greenwood BM (2003) Mass administrations of antimalarial drugs. Trends Parasitol 19:452-460

    8. WHO (2015) Malaria: draft global technical strategy: post 2015. World Health Organization, Geneva. WHA68/A68_28-en.pdf?ua=1

    9. WHO (2011) Global plan for artemisinin resistance containment. World Health Organization, Geneva, pp 1-88

    10. WHO (2013) Emergency response to artemisinin resistance in the greater Mekong subregion. Regional Framework for action 2013-2015. World Health Organization, Geneva, pp 1-32

  • Related Research Results (1)
  • Similar Research Results (1)
  • Metrics
    No metrics available
Share - Bookmark